A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
NCT04024761
Active Not Recruiting
This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hematopoietic cell transplantation (haplo-HCT) or HLA matched stem cells. This study will also study CIML NK cell infusion combined with IL-2 in pediatric patients (12 years of age or older) with AML, MDS,... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/10/2025
Locations: Boston Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Juvenile Myelomonocytic Leukemia
Register for Updates
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT00576979
Active Not Recruiting
RATIONALE: Giving intensity modulated radiation therapy (IMRT) and chemotherapy, such as etoposide and cyclophosphamide, before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a... Read More
Gender:
ALL
Ages:
Between 7 years and 55 years
Trial Updated:
03/10/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Leukemia
Register for Updates
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL
NCT03666000
Recruiting
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +21 locations
Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Register for Updates
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
NCT04262843
Recruiting
This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal organs and graft-versus-host disease (a complication after transplantation in which donor's immune cells recognize the host as foreign and attack the recipient's... Read More
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
03/06/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome
Register for Updates
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
NCT04895761
Active Not Recruiting
The study seeks to establish the safety of neoadjuvant aromatase inhibitor with: DPX-Survivac, DPX-Survivac plus radiation, or DPX-Survivac with cyclophosphamide in stage I to III HR+HER2- breast cancer. There will be sequential enrollment into 3 arms with an anticipated N=6 participants per arm for N=18 participants in total. All participants will receive letrozole 2.5 mg daily during the 6 weeks of neoadjuvant therapy. Neoadjuvant therapy occurs weeks 1-6, with standard of care surgery taking... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Breast Cancer
Register for Updates
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
NCT02950259
Active Not Recruiting
The goal of this study is assess the safety and tolerability of the IRX-2 regimen in patients with early stage breast cancer (ESBC) and to estimate the pathologic complete response rate to neoadjuvant anthracycline-based and non-platinum containing chemotherapy in patients with triple-negative breast cancer who have received the IRX-2 Regimen before chemotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
03/06/2025
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Breast Neoplasm, Breast Neoplasm, Male, Triple Negative Breast Cancer
Register for Updates
Allo HSCT for High Risk Hemoglobinopathies
NCT06872333
Recruiting
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Gender:
ALL
Ages:
55 years and below
Trial Updated:
03/06/2025
Locations: Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Register for Updates
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
NCT01804634
Recruiting
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
Gender:
ALL
Ages:
Between 1 year and 50 years
Trial Updated:
03/06/2025
Locations: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida +3 locations
Conditions: Refractory and/or Relapsed Metastatic Solid Tumors
Register for Updates
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
NCT03910452
Active Not Recruiting
Background: CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used. Researchers want to see if they can lower the risks of using a mismatched donor. Objectives: To see if it is safe to use a related bone marrow donor who is only a partial match to a person with CGD. To see how well drugs given to a person before and after transplant help the body accept the transplant. Eligibility: People ages 4-6... Read More
Gender:
ALL
Ages:
Between 4 years and 65 years
Trial Updated:
03/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Chronic Granulomatous Disease
Register for Updates
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
NCT02389309
Active Not Recruiting
This phase I trial studies the side effects and best dose of dasatinib and temsirolimus when given together with cyclophosphamide in treating patients with solid tumors that have spread to other places in the body, have come back, or have not respond to previous treatment. Dasatinib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cel... Read More
Gender:
ALL
Ages:
Between 12 months and 20 years
Trial Updated:
03/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Brain Neoplasm
Register for Updates
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
NCT02994927
Completed
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/04/2025
Locations: Clinical Trial Site, Huntsville, Alabama +197 locations
Conditions: ANCA-Associated Vasculitis
Register for Updates
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
NCT00572169
Active Not Recruiting
With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Arkansas for Medical Sciences/Myeloma Institute, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates